Stocks · News reference
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced presentations
Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the
JP Morgan analyst Jessica Fye reinstates Stoke Therapeutics (NASDAQ:STOK) with a Overweight and announces $40 price target.
Guggenheim analyst Yatin Suneja reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $60 price target.